US Rheumatologists Teed Up for Rapid Adoption of BMS' Orencia in Psoriatic Arthritis, Though the Real Game Changer Could Come with the Approval of Pfizer's Xeljanz
Half of all surveyed rheumatologists agree a new oral small molecule would be of greater use in psoriatic arthritis than any additional alternative mechanism of action biologic, according to recent fi...
Page (1) of 1 - 10/20/17||
(October 20, 2017)
This article is no longer available,but here are some related topics.
HTN - Health Technology Net
DMN Newswire Newsletter
All Rights Reserved